Chronic pelvic pain affects millions—a total market size as big as diabetes—but stigma keeps sufferers silent. H3Pelvic Therapy Systems provides dignified, effective solutions that deliver real relief where traditional care falls short.
With over $450,000 secured in grants, three patents earned, and an NIH Phase II Commercialization Review completed with a top-tier score of 27, H3Pelvic has unlocked $2.2 million in additional non-dilutive funding. The technology is validated, the intellectual property is protected, and product-market fit has been confirmed through early successful MVP distribution and customer discovery.
H3Pelvic is now positioned for rapid commercialization and scale. With an FDA-requested De Novo submission planned for 2027, manufacturing partnerships in development, and clinical studies set to generate real-world evidence, the company is ready to deliver a new platform and standard of care across more than 15 different pelvic pain indications. Operating in a $50 billion U.S. market, this is a capital-efficient opportunity in a large, underserved space—backed by federal validation, proven traction, and a clear path to revenue.